.Competing interests.R.S., M.S., H.G. and A.A.R. are coordinators of the 1M1M campaign. H.G. and A.A.R. are board of supervisors members and also R.S., M.S. as well as A.A.R. are actually participants of the scientific advising committee of N1C. A.A.R. reveals job by LUMC, which possesses licenses on exon-skipping modern technology, a few of which has actually been licensed to BioMarin and also consequently sublicensed to Sarepta. As co-inventor of a few of these licenses, A.A.R. was qualified to an allotment of nobilities. A.A.R. further makes known working as expert for PTC Rehabs, Sarepta Therapeutics, Regenxbio, Dyne Rehabs, Lilly, BioMarin Pharmaceuticals Inc., Eisai, Entrada, Takeda, Splicesense, Galapagos, Sapreme, Italfarmaco and also Astra Zeneca. Before 5 years, A.A.R. also conducted consulting with for Alpha Anomeric. A.A.R. additionally states subscription of the medical advisory boards of Eisai, Hybridize Therapeutics, Silence Therapies, Sarepta Therapies, Sapreme and also Mitorx. In the past 5 years, A.A.R. was actually also a clinical advisory board participant for ProQR. Remuneration for A.A.R. u00e2 s consulting as well as suggesting activities is actually paid out to LUMC. In the past 5 years, LUMC also acquired sound speaker honoraria coming from PTC Therapies, Alnylam Netherlands, Italfarmaco as well as Pfizer as well as funding for agreement analysis from Sapreme, Eisai, Galapagos, Synaffix and also Alpha Anomeric. Task financing is actually received from Sarepta Therapeutics and Entrada by means of unconstrained gives. H.G. possesses absolutely nothing to disclose in relation to the subjects covered in this particular composition. Over the last 5 years, he has additionally received working as a consultant honoraria coming from UCB. M.S. received working as a consultant gratuity from Ionis, UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly and also Solaxa over the last 5 years, all unassociated to the here and now manuscript. R.S. possesses nothing to disclose in connection with the subject matters covered in this manuscript. She has acquired audio speaker and/or consultancy gratuity or even financing additions coming from Abbvie, Bial, STADA and also Everpharma previously 5 years.